On January 3, 2017, Avadel Pharmaceuticals plc issued a press
release announcing that Flamel Technologies S.A. (the predecessor
of Avadel Pharmaceuticals plc) completed its cross-border merger
with and into its wholly-owned Irish subsidiary, Avadel
Pharmaceuticals plc (NASDAQ:AVDL) (“Avadel”), effective January
1, 2017, with Avadel surviving the merger as the public holding
company. A copy of the press release is furnished as Exhibit 99.1
to this current report on Form 8-K and is incorporated herein by
reference.

On January 3, 2017, Avadel Pharmaceuticals plc issued a press
release announcing the appointment of Gregory J. Divis as
Executive Vice President and Chief Commercial Officer. A copy of
the press release is furnished as Exhibit 99.2 to this current
report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits